vs
Side-by-side financial comparison of ASTROTECH Corp (ASTC) and Gain Therapeutics, Inc. (GANX). Click either name above to swap in a different company.
ASTROTECH Corp is the larger business by last-quarter revenue ($148.0K vs $105.4K, roughly 1.4× Gain Therapeutics, Inc.). ASTROTECH Corp runs the higher net margin — -2653.4% vs -4255.7%, a 1602.3% gap on every dollar of revenue. ASTROTECH Corp produced more free cash flow last quarter ($-4.0M vs $-6.1M).
Astrotech Corporation, formerly Spacehab Inc., is a technology incubator headquartered in Austin, Texas. Astrotech uses technology sourced internally and from research institutions, government laboratories, and universities to fund, manage and sell start-up companies. Astrotech Corporation's subsidiaries provide commercial products and services to NASA, the U.S. Department of Defense, national space agencies, and global commercial customers.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
ASTC vs GANX — Head-to-Head
Income Statement — Q2 FY2026 vs Q3 FY2024
| Metric | | |
|---|---|---|
| Revenue | $148.0K | $105.4K |
| Net Profit | $-3.9M | $-4.5M |
| Gross Margin | 5.4% | — |
| Operating Margin | -2635.8% | -4230.3% |
| Net Margin | -2653.4% | -4255.7% |
| Revenue YoY | -43.3% | — |
| Net Profit YoY | 2.0% | 4.9% |
| EPS (diluted) | — | $-0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $148.0K | — | ||
| Q3 25 | $297.0K | — | ||
| Q2 25 | $220.0K | — | ||
| Q1 25 | $534.0K | — | ||
| Q4 24 | $261.0K | — | ||
| Q3 24 | — | $105.4K | ||
| Q2 24 | — | $84.5K | ||
| Q1 24 | — | $115.3K |
| Q4 25 | $-3.9M | — | ||
| Q3 25 | $-3.5M | — | ||
| Q2 25 | $-2.9M | — | ||
| Q1 25 | $-3.6M | — | ||
| Q4 24 | $-4.0M | — | ||
| Q3 24 | — | $-4.5M | ||
| Q2 24 | — | $-8.1M | ||
| Q1 24 | — | $-4.0M |
| Q4 25 | 5.4% | — | ||
| Q3 25 | 63.3% | — | ||
| Q2 25 | 33.6% | — | ||
| Q1 25 | 44.4% | — | ||
| Q4 24 | 59.4% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -2635.8% | — | ||
| Q3 25 | -1190.6% | — | ||
| Q2 25 | -1326.4% | — | ||
| Q1 25 | -724.2% | — | ||
| Q4 24 | -1655.6% | — | ||
| Q3 24 | — | -4230.3% | ||
| Q2 24 | — | -9680.3% | ||
| Q1 24 | — | -3796.7% |
| Q4 25 | -2653.4% | — | ||
| Q3 25 | -1166.7% | — | ||
| Q2 25 | -1331.8% | — | ||
| Q1 25 | -680.3% | — | ||
| Q4 24 | -1536.0% | — | ||
| Q3 24 | — | -4255.7% | ||
| Q2 24 | — | -9633.2% | ||
| Q1 24 | — | -3481.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.17 | ||
| Q2 24 | — | $-0.42 | ||
| Q1 24 | — | $-0.22 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.0M | $12.0M |
| Total DebtLower is stronger | — | $494.4K |
| Stockholders' EquityBook value | $15.5M | $8.9M |
| Total Assets | $19.7M | $14.4M |
| Debt / EquityLower = less leverage | — | 0.06× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.0M | — | ||
| Q3 25 | $11.3M | — | ||
| Q2 25 | $15.1M | — | ||
| Q1 25 | $18.1M | — | ||
| Q4 24 | $21.5M | — | ||
| Q3 24 | — | $12.0M | ||
| Q2 24 | — | $16.9M | ||
| Q1 24 | — | $12.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $494.4K | ||
| Q2 24 | — | $486.4K | ||
| Q1 24 | — | $507.7K |
| Q4 25 | $15.5M | — | ||
| Q3 25 | $19.1M | — | ||
| Q2 25 | $22.1M | — | ||
| Q1 25 | $24.8M | — | ||
| Q4 24 | $28.1M | — | ||
| Q3 24 | — | $8.9M | ||
| Q2 24 | — | $11.8M | ||
| Q1 24 | — | $8.6M |
| Q4 25 | $19.7M | — | ||
| Q3 25 | $23.2M | — | ||
| Q2 25 | $27.0M | — | ||
| Q1 25 | $27.5M | — | ||
| Q4 24 | $31.0M | — | ||
| Q3 24 | — | $14.4M | ||
| Q2 24 | — | $19.2M | ||
| Q1 24 | — | $14.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.06× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | 0.06× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.5M | $-6.1M |
| Free Cash FlowOCF − Capex | $-4.0M | $-6.1M |
| FCF MarginFCF / Revenue | -2671.6% | -5764.6% |
| Capex IntensityCapex / Revenue | 277.7% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-14.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-3.5M | — | ||
| Q3 25 | $-3.9M | — | ||
| Q2 25 | $-2.4M | — | ||
| Q1 25 | $-3.9M | — | ||
| Q4 24 | $-3.0M | — | ||
| Q3 24 | — | $-6.1M | ||
| Q2 24 | — | $-5.8M | ||
| Q1 24 | — | $-3.6M |
| Q4 25 | $-4.0M | — | ||
| Q3 25 | $-4.4M | — | ||
| Q2 25 | $-2.7M | — | ||
| Q1 25 | $-3.9M | — | ||
| Q4 24 | $-3.4M | — | ||
| Q3 24 | — | $-6.1M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -2671.6% | — | ||
| Q3 25 | -1476.1% | — | ||
| Q2 25 | -1231.4% | — | ||
| Q1 25 | -728.1% | — | ||
| Q4 24 | -1288.5% | — | ||
| Q3 24 | — | -5764.6% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 277.7% | — | ||
| Q3 25 | 150.8% | — | ||
| Q2 25 | 158.2% | — | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 122.2% | — | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
